SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on August 10, 2023. The filing serves to report the Company's financial results for the quarter ended June 30, 2023, as detailed in a press release furnished as Exhibit 99.1. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the Q2 2023 financial results.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The Company disclosed its channels for communicating material information, including its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Instagram, Facebook).
Unusual Items: None identified in the text of this specific 8-K form.
Guidance: No forward-looking guidance or outlook figures are present in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q2 2023 financial figures (revenue, net loss, cash position).
- Verify the Company's status as an Emerging Growth Company and any associated accounting election impacts.
- Check the Company's official website and social media channels for any additional material disclosures referenced in Item 7.01.
- Confirm the trading symbol ATHA on The Nasdaq Global Select Market.